Cybersecurity's Past, Present, and AI-Driven Future

The federal agency known as the FDA, or the Food and Drug Administration, was born over 100 years ago—at the turn of the industrial revolution, in a time of enormous upheaval and change, and rapidly emerging technology. The same could be said to be just as true today. From CRISPR to synthetic biology to using artificial intelligence in medicine, our healthcare system is undergoing massive amounts of innovation and change. Covering everything from gene-editing your dog to tracking the next foodborne outbreak, this wide-ranging conversation between Principal Commissioner of the FDA Amy Abernethy and Vijay Pande, GP on the Bio Fund at a16z, discusses how the agency is evolving to keep pace with the scientific breakthroughs coming, while staying true to its core mission of assessing safety and effectiveness for consumers in the world of food and medicine. Highlights:What the FDA looks like today and the key steps of the FDA process to getting a drug/product to market [2:20] How to manage a culture when mitigating risk is a top priority while aiming to innovate for the future [5:22] Creative problem-solving in times of crisis, such as the Opioid crisis [9:58] Preparing for and preventing drug shortages at scale [13:30] How advances in bioengineering are transforming healthcare [16:00] How the FDA is thinking about n=1 therapies and its applications in the future [18:54] The future of healthcare privacy [26:10] The ways the clinical trial process are shifting [29:26] Innovations in Bioengineering as they relate to regulating food in the future [36:02] How the FDA handles foodborne illnesses and its plans to innovate food safety [39:12] Discussion about the next 100 years of the FDA [41:25]

14 Jan 202044min

How does the world’s largest producer of medicines in terms of volume balance the science and the business of innovation? How does an enterprise at such vast scale make decisions about what to build vs. buy, especially given the fast pace of science today? How does it balance attitudes between “not invented here” and “not invented yet”?Vas Narasimhan, CEO of Novartis, sat down with a16z bio general partners Jorge Conde and Vijay Pande, and editor in chief Sonal Chokshi, during the JP Morgan Healthcare Conference around this time last year, to discuss the latest trends in therapeutics; go to market and why both big companies and bio startups need to get market value signals (not just approvals!) from payers earlier in the process; clinical trials, talent, leadership, and more in this rerun of the a16z Podcast. image: Global Panorama/ Flickr

11 Jan 202059min

This is a turn of the decade (and January-themed) look backward/ look forward into personal genomics, given recent and past retrospective and prospective pieces in the media on the promise, and perils, of the ability to sequence one's DNA: What did it, and does it, mean for personalized medicine, criminal investigations, privacy, and more?General partner Jorge Conde, who has a long history in the space, covers everything from where genealogy databases and large datasets come in to fetal testing, multi-omics, and other themes spanning the past, present, and future of personal genomics in conversation with Sonal Chokshi for episode #18 our news show 16 Minutes, where we cover recent headlines, the a16z way, from our vantage point in tech -- and especially what's hype/ what's real. While we typically cover multiple headlines, this is one of our special deep-dive episodes on a single topic. (You catch up on other such deep dives, on the opioid crisis and other evergreen episodes, at a16z.com/16Minutes). And if you haven't already, be sure to subscribe to the separate feed for "16 Minutes" to continue getting new episodes. image: Petra Fritz / Flickr

6 Jan 202019min

Many skeptics thought the internet would never reach mass adoption, but today it’s shaping global culture, is integral to our lives -- and it's just the beginning. In this conversation from our 2019 innovation summit, Kevin Kelly (Founding Executive Editor, WIRED magazine) and Marc Andreessen sit down to discuss the evolution of technology, key trends, and why they're the most optimistic people in the room.***The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

2 Jan 202044min

When innovation and capital go global, so do restrictions on trade, foreign investment, and more. Over the past couple years, U.S. policymakers have expanded the scope of the Committee on Foreign Investment in the U.S. (CFIUS) through the Foreign Investment Risk Review Modernization Act (FIRRMA) of 2018 which was recently updated through proposed reforms this September 2019.So what does this all mean for tech founders taking investments from, or doing joint ventures with, foreign entities -- or just doing business globally in general? What does and doesn't CFIUS cover, and how might one structure partnerships strategically as a result? In this episode, a16z general partner Katie Haun interviews Michael Leiter (of law firm Skadden Arps) who specializes in CFIUS as well as matters involving U.S. national security and cybersecurity, cross-border transactions, aerospace and defense mergers and acquisitions, and government relations and investigations.The Q&A took place in September 2019 as part of an event hosted by Andreessen Horowitz. The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

23 Dec 201946min

A bold proposal: You go to college for free, then pay back the school after graduation—but only if you get a job in your field of study and make a high enough salary to afford it. It's called an income share agreement, and Austen Allred, the CEO and cofounder of Lambda School, thinks it's the future of education.Student debt currently stands at more than 1.5 trillion dollars, which makes it the second-highest consumer debt category behind mortgage debt. The crisis has saddled much of a generation, with far reaching effects. Income share agreements, or ISAs, have been put forth as an alternative to the current system. Put simply, an ISA is an agreement between a school and a student for the student to pay a defined percentage of income to the school, for a particular period of time, up to a certain cap. It's a seemingly simple conceit with complex design considerations, and it's spurring debate across media and politics.In this episode, Lambda School CEO Austen Allred, a16z general partner D'Arcy Coolican, and a16z editorial partner Lauren Murrow delve into the greater implications ISAs may have for education and the economy. The discussion covers both the promise and the challenges of ISAs—why they've been relatively slow to gain traction, why they've failed in the past, and why some in the political sphere are still skeptical.

19 Dec 201927min

Hollywood and Silicon Valley seem so different, but are more alike than we think. What challenges do tech startup founders and other creative founders -- like showrunners and executive producers -- similarly face? Both have to deeply understand and respect their audiences; learn how to scale themselves beyond one person; and even figure out how and when to use data... or follow their intuitions.In the end, it’s all about creating a story (product!) that sticks.In this conversation with Andreessen Horowitz cofounder and general partner Marc Andreessen, Shonda Rhimes -- executive producer, writer, creator of hit 100+ episode shows hows like Grey’s Anatomy and Scandal, and founder of the media company Shondaland -- shares the mindsets that drive her to pitch ideas, think about new mediums, and what happens when make believe veers too close to reality.Rhimes is the recipient of several industry awards and accolades, including a Golden Globe for Outstanding Television Drama, the Peabody Award, Time 100 most influential people, Fortune's “50 Most Powerful Women in Business", and lifetime achievement awards from the Directors Guild of America, the Writers Guild of America, and the Producers Guild of America. She has been inducted into the National Association of Broadcasters Broadcasting Hall of Fame and to the Television Academy of Arts & Sciences Hall of Fame. She is also the creative director of Dove’s #RealBeauty campaign and authored NYT bestseller Year of Yes.The conversation originally took place at our most recent annual innovation Summit -- which features a16z speakers and invited experts from various organizations discussing innovation at companies large and small, as well as tech trends spanning bio, consumer, crypto, fintech, and more.

17 Dec 201934min

As part of a new series where we will share select a16z partner appearances on other podcasts with our audience here, this episode is cross-posted from the new show Starting Greatness -- featuring interviews with startup builders before they were successful -- hosted by Mike Maples junior.In the conversation, a16z co-founder Marc Andreessen shares some rare, behind-the-scenes details of his story from 0 to 1 -- from the University of Illinois and Mosaic to Netscape -- and along the journey, really, to product-market fit...

17 Dec 201944min